Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies.

High heterogeneity and an immunosuppressive tumor microenvironment (TME) are the core therapeutic bottlenecks of digestive system tumors. Current monotherapies face prominent limitations: immune checkpoint inhibitors (ICIs) yield low overall response rates as single agents, while long-term use of anti-angiogenic drugs (AADs) easily induces tumor resistance. To overcome these drawbacks, AAD-ICI combination therapy has become a research hotspot in this field, whose core synergy lies in coordinated TME modulation. AADs promote vascular normalization and reverse immunosuppressive TME to enhance intratumoral T lymphocyte infiltration, thereby laying a foundation for ICIs to exert anti-tumor effects and reactivating the endogenous anti-tumor immune response. Natural compounds have drawn extensive attention due to their regulatory value in TME remodeling and tumor combination therapy. However, there is still a lack of a comprehensive and systematic summary of their specific roles, molecular mechanisms and latest research progress in anti-angiogenic therapy, ICIs and their combination regimens for digestive system tumors. This deficiency impedes the further development of this research field. To fill this critical void, this review systematically elaborates the underlying mechanisms and clinical advances of AAD-ICI combination therapy for digestive system tumors. It also summarizes the regulatory functions and relevant research evidence of natural compounds in this therapeutic system, including those with dual regulatory effects. Additionally, the review analyzes existing challenges in basic research and clinical application, and outlines future research priorities. This work is expected to provide a valuable reference for the clinical translation and regimen optimization of precision immunotherapy for digestive system tumors.

• Publication year

  2026

• Venue

  Biochimica et biophysica acta. Reviews on cancer

• Publication date

  2026-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2026.189564PMID 41722625
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.

  2025cited by this paper
• Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma

  2025cited by this paper
• Co-Delivery of Chemotherapy and Anti-Angiogenic Lipid via DPPA-LNPs Potentiates Anti-PD-1 Immunotherapy

  2025cited by this paper
• Effectiveness and mechanisms of Curcumin for colorectal cancer in preclinical models:A systematic review and meta-analysis.

  2025cited by this paper
• Delivery of an ERK inhibitor using bioactive lipid nanoparticles reduces angiogenesis and prevents oral squamous cell carcinoma development

  2025cited by this paper
• Combination of Ginsenoside Compound K and Anti-PD1 Inhibits Pancreatic Cancer by Activating CXCL13-CXCR5 Signaling Axis.

  2025cited by this paper
• Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

  2025cited by this paper
• Anti-Colorectal Cancer Activity of Panax and Its Active Components, Ginsenosides: A Review

  2025cited by this paper
• Natural flavonoid Orientin restricts 5-Fluorouracil induced cancer stem cells mediated angiogenesis by regulating HIF1α and VEGFA in colorectal cancer

  2025cited by this paper
• Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer.

  2025cited by this paper
• First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.

  2025cited by this paper
• Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

  2025cited by this paper
• Digestive cancers: mechanisms, therapeutics and management

  2025cited by this paper
• Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy

  2024cited by this paper
• Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

  2024cited by this paper
• Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study

  2024cited by this paper
• Angiogenic protein profiling, phytochemical screening and in silico anti-cancer targets validation of stem, leaves, fruit, and seeds of Calotropis procera in human liver and breast cancer cell lines.

  2024cited by this paper
• The mechanism of Xihuang pills' intervention in the tumour immune microenvironment for the treatment of liver cancer based on the STAT3-PDL1 pathway.

  2024cited by this paper
• EGCG suppresses PD-1 expression of T cells via inhibiting NF-κB phosphorylation and nuclear translocation.

  2024cited by this paper
• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cited by this paper
• A lipid/PLGA nanocomplex to reshape tumor immune microenvironment for colon cancer therapy

  2024cited by this paper
• The Tumor Microenvironment Mediates the HIF-1α/PD-L1 Pathway to Promote Immune Escape in Colorectal Cancer

  2024cited by this paper
• Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

  2024cited by this paper
• Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

  2024cited by this paper
• Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis

  2024cited by this paper
• LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.

  2024cited by this paper
• Ginsenoside Rg3 suppresses vasculogenic mimicry by impairing DVL3-maintained stemness via PAAD cell-derived exosomal miR-204 in pancreatic adenocarcinoma.

  2024cited by this paper
• VEGF signaling: Role in angiogenesis and beyond.

  2024cited by this paper
• Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.

  2024cited by this paper
• Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3

  2024cited by this paper
• Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

  2024cited by this paper
• Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial

  2024cited by this paper
• Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial

  2024cited by this paper
• Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.

  2024cited by this paper
• Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

  2024cited by this paper
• Tumour mutational burden: clinical utility, challenges and emerging improvements

  2024cited by this paper
• Exploring treatment options in cancer: tumor treatment strategies

  2024cited by this paper
• Bioactive Nanotherapeutic Ultrasound Contrast Agent for Concurrent Breast Cancer Ultrasound Imaging and Treatment

  2024cited by this paper
• Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours

  2024cited by this paper
• First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

  2024cited by this paper
• Antiangiogenic potential of Lepista nuda extract suppressing MAPK/p38 signaling-mediated developmental angiogenesis in zebrafish and HUVECs.

  2023cited by this paper
• Biology and therapeutic targeting of vascular endothelial growth factor A

  2023cited by this paper
• LAG-3 as the third checkpoint inhibitor

  2023cited by this paper
• Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

  2023cited by this paper
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer

  2023cited by this paper
• Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.

  2023cited by this paper
• The extract of Curcumae Longae Rhizoma suppresses angiogenesis via VEGF-induced PI3K/Akt-eNOS-NO pathway.

  2023cited by this paper
• Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study

  2023cited by this paper
• Liujunzi decoction exerts potent antitumor activity in oesophageal squamous cell carcinoma by inhibiting miR-34a/STAT3/IL-6R feedback loop, and modifies antitumor immunity.

  2023cited by this paper
• Sesamin Attenuates VEGFA-Induced Angiogenesis via Inhibition of Src and FAK Signaling in Chick Chorioallantoic Membrane Model and Human Endothelial EA.hy926 Cells

  2023cited by this paper
• Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3β/TCF7/MMP9 pathway and synergies with capecitabine.

  2023cited by this paper
• Akkermansia muciniphila might improve anti‐PD‐1 therapy against HCC by changing host bile acid metabolism

  2023cited by this paper
• Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10.

  2023cited by this paper
• Radix Bupleuri-Radix Paeoniae Alba Inhibits the Development of Hepatocellular Carcinoma through Activation of the PTEN/PD-L1 Axis within the Immune Microenvironment

  2023cited by this paper
• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.

  2023cited by this paper
• Checkpoint inhibitors and anti-angiogenic agents: a winning combination

  2023cited by this paper
• Natural products targeting tumour angiogenesis

  2023cited by this paper
• Immune Interactions in Pembrolizumab (PD-1 Inhibitor) Cancer Therapy And Cardiovascular Complications.

  2023cited by this paper
• Vascular Permeability in Diseases

  2022cited by this paper
• Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.

  2022cited by this paper
• Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets

  2022cited by this paper
• Myricetin reverses epithelial–endothelial transition and inhibits vasculogenic mimicry and angiogenesis of hepatocellular carcinoma by directly targeting PAR1

  2022cited by this paper
• Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

  2022cited by this paper
• Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

  2022cited by this paper
• Cancer combination therapies by angiogenesis inhibitors; a comprehensive review

  2022cited by this paper
• Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

  2022cited by this paper
• Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways

  2022cited by this paper
• A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.

  2022cited by this paper
• Flavonoids-Based Delivery Systems towards Cancer Therapies

  2022cited by this paper
• Plant-derived bioactive compounds in colon cancer treatment: An updated review.

  2022cited by this paper
• Novel artemisinin derivative FO8643 with anti-angiogenic activity inhibits growth and migration of cancer cells via VEGFR2 signaling.

  2022cited by this paper
• Sesamin inhibits hypoxia-stimulated angiogenesis via the NF-κB p65/HIF-1α/VEGFA signaling pathway in human colorectal cancer.

  2022cited by this paper
• Artemisinin derivative FO-ARS-123 as a novel VEGFR2 inhibitor suppresses angiogenesis, cell migration, and invasion.

  2022cited by this paper
• Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges

  2022cited by this paper
• A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

  2022cited by this paper
• The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy

  2022cited by this paper
• Thymoquinone Suppresses Angiogenesis in DEN-Induced Hepatocellular Carcinoma by Targeting miR-1-3p

  2022cited by this paper
• Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy.

  2022cited by this paper
• Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti‐PD‐1 efficacy

  2022cited by this paper
• Ginsenoside Rg3 inhibits angiogenesis in gastric precancerous lesions through downregulation of Glut1 and Glut4.

  2021cited by this paper
• Anticancer Effects of the Corchorus olitorius Aqueous Extract and Its Bioactive Compounds on Human Cancer Cell Lines

  2021cited by this paper
• Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

  2021cited by this paper
• (20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2

  2021cited by this paper
• Crocetin suppresses angiogenesis and metastasis through inhibiting sonic hedgehog signaling pathway in gastric cancer.

  2021cited by this paper
• PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.

  2021cited by this paper
• The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer

  2021cited by this paper
• Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

  2021cited by this paper
• Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL-6/JAK/STAT3-mediated PD-L1 activity

  2021cited by this paper
• Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

  2021cited by this paper
• First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

  2021cited by this paper
• FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

  2021cited by this paper
• Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

  2021cited by this paper
• Quercetin inhibits invasion and angiogenesis of esophageal cancer cells.

  2021cited by this paper
• Nephrotoxicity of Anti-Angiogenic Therapies

  2021cited by this paper
• Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy

  2021cited by this paper
• Tanshinone IIA reduces secretion of pro-angiogenic factors and inhibits angiogenesis in human colorectal cancer

  2020cited by this paper
• Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy

  2020cited by this paper
• Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells.

  2020cited by this paper
• Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.

  2020cited by this paper
• Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

  2020cited by this paper

• No citing papers are available for this paper.